Table 4

Characteristics of the study group of 147 patients treated with imatinib for late chronic-phase chronic myelogenous leukemia and starting with 100% Philadelphia-positive cells, and of the historical control group of 95 patients treated with IFN for late chronic-phase chronic myelogenous leukemia

Characteristic no. treatedPercentage
CategoryImatinibIFN-basedP
Age (years)≥60399<0.0001
SplenomegalyPresent14250.04
Hemoglobin (g/dl)<1243370.42
WBC (×109/l)>5014310.004
Platelets (×109/l)>45029370.23
% marrow blasts≥51480.15
Peripheral blastsPresent27400.04
% marrow basophils≥424150.12
% peripheral basophils≥715170.83
Cytogenetic clonal evolutionYes13170.51
Prognostic group (20)Low4554
Intermediate48380.60
High78
Duration of chronic phase (months)12–3548570.20
≥355243
IFN failureHematologic19
Cytogenetic51
Intolerance30